Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer

详细信息    查看全文

• 作者：Xing Hua (1) (2) (3) (4)
  Lina Yu (1) (2)
  Wenhai Pan (5) (6)
  Xiaoxiao Huang (3) (4)
  Zexiao Liao (3) (4)
  Qi Xian (3) (4)
  Li Fang (3) (4)
  Hong Shen (1) (2)
  
• 关键词：Prostate cancer ; Castration resistant ; Golgi phosphoprotein ; 3 ; Prognosis ; Tissue microarrays
• 刊名：Diagnostic Pathology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：7
• 期：1
• 全文大小：558KB
• 参考文献：1. Niu Z, Guohua R, Shuping S: Diagnosis and treatment for prostate cancer. Chinese–German. / J Clin Oncol 2008, 7:492-94.
  2. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. / N Engl J Med 2004, 351:1488-490. CrossRef
  3. Fritzsche FR, Stephan C, Gerhardt J, Lein M, Hofmann I, Jung K, Dietel M, Kristiansen G: Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. / Histol Histopathol 2010, 25:733-39.
  4. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson LM: Biomarkers for prostate cancer detection. / J Urol 2007, 178:2252-259. CrossRef
  5. Dippold HC, Ng MM, Farber-Katz SE: GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. / Cell 2009, 139:337-51. CrossRef
  6. Wood CS, Schmitz KR, Bessman NJ: PtdIns4P recognition by Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking. / J Cell Biol 2009, 187:967-75. CrossRef
  7. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhaka S, Wu M, Chen SJ, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao YH, Rimm DL, Protopopov A, Wong KK, Chin L: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. / Nature 2009, 459:1085-090. CrossRef
  8. Abraham RT: GOLPH3 links the Golgi network to mTOR signaling and human cancer. / Pigment Cell Melanoma Res 2009, 22:378-79. CrossRef
  9. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. / Nat Med 1998, 4:844-47. CrossRef
  10. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T: Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. / Med Oncol 2012, 29:406-10. CrossRef
  11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. / CA Cancer J Clin 2006, 56:106-30. CrossRef
  12. Levi M: Cancer and DIC. / Haemostasis 2001, 31:47-8.
  13. de la Fouchardière C, Flechon A, Droz JP: Coagulopathy in prostate cancer. / Neth J Med 2003, 61:347-54.
  14. Wedel S, Hudak L, Seibel J-M, Makarevic J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA: Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. / BMC Cancer 2011, 11:375. CrossRef
  15. Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS: Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. / BJU Int 2009, 103:43-8. CrossRef
  16. Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A, Este CD: PSA response signatures -a powerful new prognostic indicator after radiation for prostate cancer? / Radiother Oncol 2009, 90:382-88. CrossRef
  17. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, Amico AVD: Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer. / Clin Cancer Res 2004, 10:3927-933. CrossRef
  18. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute M: Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: Impact on prostate cancer specific survival. / J Urol 2006, 175:547-51. CrossRef
  19. Helpap B, Egevad L: Modified Gleason grading. An updated review. / Histol Histopathol 2009, 24:661-66.
  20. Hara N, Kitamura Y, Saito T, Komatsubara S: Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. / Asian J Androl 2006, 8:429-34. CrossRef
  21. Bin W, He W, Feng Z, Xiangdong L, Yong C, Lete K, Hongbin Z, Honglin G: Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer. / Acta Histochem 2011, 113:131-36. CrossRef
  22. Isaacs JT, Wake N, Coffey DS, Sandberg AA: Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. / Cancer Res 1982, 42:2353-371.
  23. Miyake H, Tolcher A, Gleave ME: Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgenindependence after castration in the Shionogi tumor model. / Cancer Res 1999, 59:4030-034.
  24. Miyake H, Nelson C, Rennie PS, Gleave ME: Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. / Cancer Res 2000, 60:170-76.
  25. Miyake H, Pollak M, Gleave ME: Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen-independence in prostate cancer models. / Cancer Res 2000, 60:3058-064.
  26. Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L: c-Jun can mediate androgen receptorinduced transactivation. / J Biol Chem 1996, 271:24583-4589. CrossRef
  27. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein–protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. / J Biol Chem 1997, 272:17485-7494. CrossRef
  28. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancerthrough modulation of androgen receptor signalingby the HER-/neu tyrosine kinase. / Nat Med 1999, 5:280-85. CrossRef
  29. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. / Genes Dev 2002, 16:1472-487. CrossRef
  30. Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. / Proc Natl Acad Sci USA 2005, 102:8204-209. CrossRef
  31. Jacinto E, Hall MN: Tor signalling in bugs, brain and brawn. / Nat Rev Mol Cell Biol 2003, 4:117-26. CrossRef
  32. Oldham S, Hafen E: Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. / Trends Cell Biol 2003, 13:79-5. CrossRef
  33. Schmelzle T, Hall MN: TOR, a central controller of cell growth. / Cell 2000, 103:253-62. CrossRef
  
• 作者单位：Xing Hua (1) (2) (3) (4)
  Lina Yu (1) (2)
  Wenhai Pan (5) (6)
  Xiaoxiao Huang (3) (4)
  Zexiao Liao (3) (4)
  Qi Xian (3) (4)
  Li Fang (3) (4)
  Hong Shen (1) (2)
  
  1. Department of Pathology, Nanfang Hospital, Southern Medical University, 510515, Tonghe, Guangzhou, People’s Republic of China
  2. Department of Pathology, School of Basic Medical Sciences, Southern Medical University, 510515, Tonghe, Guangzhou, People’s Republic of China
  3. Department of Pathology, the Forth Affiliated Hospital of Jinan University, Guangzhou, China
  4. Department of Pathology, Guangzhou Red Cross Hospital, Guangzhou, China
  5. Department of Urology, the Forth Affiliated Hospital of Jinan University, Guangzhou, China
  6. Department of Urology, Guangzhou Red Cross Hospital, Guangzhou, China
  

文摘

Background To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine its prognostic value. Methods Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients. The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to determine its prognostic significance. Results GOLPH3 expression of normal prostate tissues, benign prostate hyperplasia, high-grade prostatic intraepithelial neoplasia, and hormone-dependent prostate cancer (HDPC) did not show any statistically significant difference. In contrast, statistically significant difference was reported in moderate/intense GOLPH3 expression in cases diagnosed with HDPC and castration resistant prostate cancer (CRPC) (P < 0.0005). Moderate /intense expression of GOLPH3 was associated with androgen independence (P--.012), higher Gleason score (P--.017), bone metastasis (P--.024), higher baseline prostate-specific antigen (PSA) (P--.038), and higher PSA nadir (P--.032). A significantly negative correlation was found between moderate/intense GOLPH3 expression and disease-free survival (DFS) (HR--.28, P--.012) and overall survival (OS) (HR--.42, P--.027). Univariated analysis indicated that moderate/intense GOLPH3 expression created a significantly prognostic impact in patients with CRPC. On the other hand, multivariate analysis indicated that GOLPH3 was a significantly independent prognostic factor of DFS (P--.027) in all prostate cancer patients. Conclusions In this study, it was discovered that the overexpression of GOLPH3 is associated with the transition of prostate cancer from hormone sensitive phase to hormone refractory phase. GOLPH3 might be an important prognostic factor of DFS and OS in patients with prostate cancer. In totality, GOLPH3 could be used as a novel candidate in devising a more effective therapeutic strategy to tackle CRPC. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1452541171722856.